Harry W Herr1. 1. Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. herrh@mskcc.org
Abstract
OBJECTIVES: To determine the influence of age on the outcomes of high-risk superficial bladder cancer treated with intravesical bacille Calmette-Guérin (BCG) therapy. METHODS: A total of 805 patients with multiple or recurrent high-grade Ta, T1, and/or carcinoma in situ bladder cancer received BCG therapy. The endpoints were the initial response to BCG and cancer-free survival correlated with age among patients followed up for a minimum of 2 to 5 years. RESULTS: No difference was observed in the first response to BCG or cancer-free survival at 2 years among patients less than 50, 50 to 59, 60 to 69, 70 to 79, or 80 years or older. After 5 years, 27% of patients older than 70 years were cancer free compared with 37% younger than 70 years (P = 0.005). CONCLUSIONS: The results of our study have shown that aging has a measurable, but small, impact on the overall outcomes of high-risk superficial bladder cancer.
OBJECTIVES: To determine the influence of age on the outcomes of high-risk superficial bladder cancer treated with intravesical bacille Calmette-Guérin (BCG) therapy. METHODS: A total of 805 patients with multiple or recurrent high-grade Ta, T1, and/or carcinoma in situ bladder cancer received BCG therapy. The endpoints were the initial response to BCG and cancer-free survival correlated with age among patients followed up for a minimum of 2 to 5 years. RESULTS: No difference was observed in the first response to BCG or cancer-free survival at 2 years among patients less than 50, 50 to 59, 60 to 69, 70 to 79, or 80 years or older. After 5 years, 27% of patients older than 70 years were cancer free compared with 37% younger than 70 years (P = 0.005). CONCLUSIONS: The results of our study have shown that aging has a measurable, but small, impact on the overall outcomes of high-risk superficial bladder cancer.
Authors: Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes Journal: J Natl Compr Canc Netw Date: 2012-02 Impact factor: 11.908
Authors: Daher C Chade; Shahrokh F Shariat; Ari Adamy; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni Journal: J Urol Date: 2010-06-17 Impact factor: 7.450
Authors: Daher C Chade; Shahrokh F Shariat; Guilherme Godoy; Caroline J Savage; Angel M Cronin; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni Journal: J Urol Date: 2010-07 Impact factor: 7.450
Authors: Wojciech Krajewski; Oscar Rodríguez Faba; Alberto Breda; Francesca Pisano; Sławomir Poletajew; Andrzej Tukiendorf; Romuald Zdrojowy; Anna Kołodziej; Juan Palou Journal: World J Urol Date: 2020-02-18 Impact factor: 4.226
Authors: Shahrokh F Shariat; John P Sfakianos; Michael J Droller; Pierre I Karakiewicz; Siegfried Meryn; Bernard H Bochner Journal: BJU Int Date: 2009-11-13 Impact factor: 5.588